Genmab A/S (GMAB)

Market Cap	17.95B +37.8%
Revenue (ttm)	3.72B +19.2%
Net Income	963.00M -15.0%
EPS	15.37 -12.3%
Shares Out	61.62M
PE Ratio	18.64
Forward PE	23.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,924,764
Open	29.42
Previous Close	29.44
Day's Range	28.99 - 29.86
52-Week Range	17.24 - 35.43
Beta	0.80
Analysts	Strong Buy
Price Target	40.93 (+38.04%)
Earnings Date	Feb 17, 2026

About GMAB

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 2,973
• Stock Exchange: NASDAQ
• Ticker Symbol: GMAB
• Website: https://www.genmab.com

Financial Performance

In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.

Analyst Summary

According to 8 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price target is $40.93, which is an increase of 38.04% from the latest price.

Price Target

$40.93

(38.04% upside)

Analyst Consensus: Strong Buy